Walleye Capital
GMAB icon

Walleye Capital’s Genmab GMAB Stock Holding History

Walleye Capital’s Portfolio GMAB Stock Details GMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$778K Buy
+29,000
New +$869K ﹤0.01% 2305

Other funds holding GMAB

OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
HL
Harding Loevner Bridgewater, New Jersey $9.72B AUM 22.38% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Walleye Capital's GMAB Position: Q1 2026 in Review

Walleye Capital opened a new position in Genmab (GMAB) in Q1 2026: 18,907 shares worth $507K. The stake represents ﹤0.01% of the portfolio and ranks #2656 among its holdings. This is a return to the name: Walleye Capital previously reported a position in GMAB as recently as Q1 2025.

Walleye Capital first reported a position in GMAB in Q1 2025 and has held it in 2 quarters since. The position peaked at $1.39M in Q1 2025. 272 funds tracked by Wall St. Rank hold GMAB as of Q1 2026.

  • Walleye Capital held 18,907 shares of Genmab worth $507K as of Q1 2026.
  • Genmab was a new Walleye Capital position in Q1 2026.
  • Genmab made up ﹤0.01% of Walleye Capital's portfolio in Q1 2026, its #2656 holding.
  • Walleye Capital first reported a position in Genmab in Q1 2025 and has held it in 2 quarters since.
  • Walleye Capital's Genmab position peaked at $1.39M in Q1 2025.
  • 272 funds tracked by Wall St. Rank held Genmab as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.